
Stock News•1 months ago
GeneDx Holdings Securities Fraud Class Action Result of Acquisition Performance Misrepresentations and 49% Stock Decline - Investors may Contact Lewis Kahn, Esq, at Kahn Swick & Foti, LLC
GeneDx Holdings faces a securities class action over alleged misrepresentations tied to its acquisition, with shares declining 49%. Lead plaintiff applications are due August 3, 2026.














